About the Test for Oncology

Providing answers physicians need at the speed patients deserve

With the rise of precision oncology, genomic profiling is playing an increasingly large role in clinical decision making and bringing clarity to targeted treatment approaches. Across all advanced cancer types, faster answers are needed.
 

Explore the benefits of the Oncotype MAP test

Fast, actionable insights bring clarity to treatment options

Oncotype MAP packaging The Oncotype MAP Pan-Cancer Tissue test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. The test identifies actionable genomic alterations within 3-5 business days*† to guide timely treatment decisions, usually before the next follow up visit.

Utilizing next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the Oncotype MAP Pan-Cancer Tissue test identifies clinically-relevant genomic alterations from patient specimens as small as 3 mm2 of tissue with 15% tumor content, about the size of a grain of rice. Fewer Quantity Not Sufficient (QNS) samples mean more of your patients get tested and treated.

Why Choose the Oncotype MAP Pan-Cancer Tissue Test?

The Oncotype MAP Pan-Cancer Tissue test can provide in-depth insights into alterations of hundreds of cancer-related genes, usually before the patient’s next follow-up visit.

FAST

icon fast

  •   Results in 3-5 business days
  •   Quantity Not Sufficient (QNS) results typically reported within 2 business days

COMPREHENSIVE

icon comprehensive

  • >250 genes, 11 fusions
  •   22 IHC stains
  •   30+ tumor-specific panels
  •   Copy number variants
  •   Tumor mutation burden
  •   Protein expression

ACTIONABLE

icon actionable

Test assesses:
  •   100+ therapies
  •   45+ combination therapies
  •   650+ clinical trials

ACCURATE

icon accurate

  •   FNA and FFPE samples as small as 3 mm2 with ≥15% tumor content
  •   >99% sensitivity for SNVs and Indels, detection down to ≥7.5% mutant allele frequency (MAF) with >99% specificity*



Patient Eligibility

The Oncotype MAP Pan-Cancer Tissue test is most appropriate for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. The test can also provide valuable data and analysis to inform treatment decisions where no standard of care exists.


Interpreting the Report


Results are provided in an easy-to-interpret report with NCCN actionable indications for therapy, along with potential evidence-based therapies and clinical trials, to deliver treatment options for a breadth of solid tumor types.

The Oncotype MAP Pan-Cancer Tissue Test profiles a wide range of genetic structures including:
  • Single nucleotide variants (SNVs) and insertions/deletions in coding regions of the genes listed below
  • Untranslated regions (UTRs) and splice junctions when actionable, e.g. MET exon 14 skipping and EGFRvIII
  • Microsatellite instability (MSI)
  • Tumor mutational burden (SNVs, insertions, deletions) based on -1 megabase
  • Select fusions involving ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, RET, ROS1, NTRK1, NTRK2, NTRK3 (ETV6)
  • Copy number variants
VIEW 257 GENE NGS PANEL
257 Gene NGS Panel
ABCB1
ABCC1
ABCC2
ABL1
ACVR1
ACVR1B
ACVR2A
ACVR2B
ACVRL1
ADAMTS1
ADAMTS6
ADAMTS9
ADAMTS16
ADAMTS18
ADAMTSL1
AKT1
AKT2
AKT3
ALK
AMER1
APC
APLNR
AR
ARAF
AREG
ARID1A
ARID1B
ARID2
ATM
ATR
ATRX
AURKA
AURKB
AXIN1
AXL
B2M
BAP1
BARD1
BCOR
BMP6
BMPR1A
BMPR1B
BNIP3
BRAF
BRCA1
BRCA2
BRIP1
BTK
BUB1B
CALR
CBL
CCND1
CCND2
CCND3
CCNE1
CD274
CDA
CDC73
CDH1
CDK4
CKD6
CDK12
CDKN2A
CHEK1
CHEK2
CHFR
CHKA
CIC
CREBBP
CSF1R
CTLA4
CTNNB1
CYP19A1
CYP1A1
CYP2D6
CYP3A4
CYSLTR2
DCK
DDR2
DICER1
DNMT3A
EGFR
EMSY
EP300
EPCAM
EPHA5
EPHA7
ERBB2
ERBB3
ERBB4
ERCC1
ERCC2
ERCC3
ERRFI1
ESR1
ESR2
EWSR1
EZH2
FAM175A
FANCA
FANCC
FANCD2
FANCE
FANCF
FANCG
FANCM
FAT1
FBXW7
FCGR2A
FGD4
FGF3
FGF4
FGFR1
FGFR2
FGFR3
FGFR4
FLT3
FLT4
FOXL2
FUBP1
GAS6
GATA3
GLI1
GNA11
GNAQ
GNAS
GSTP1
HAMP
HDAC2
HGF
HNF1A
HRAS
HSD3B1
IDH1
IDH2
IGF1R
IKZF1
IL6R
JAK1
JAK2
JAK3
KDM5C
KDM6A
KDR
KEAP1
KIT
KRAS
MAF
MAP2K1
MAP2K2
MAP3K1
MAPK1
MAPK3
MAPKAPK5
MDM2
MDM4
MED12
MEN1
MET
MGMT
MLH1
MPL
MRE11A
MSH2
MSH6
MTHFR
MTOR
MUTYH
MYC
MYCN
MYOD1
NBN
NF1
NF2
NFE2L2
NOTCH1
NOTCH2
NOTCH3
NPMI
NRAS
NTRK1
NTRK2
NTRK3
PALB2
PBRM1
PDCD1LG2
PDGFRA
PDGFRB
PIK3CA
PIK3CB
PIK3CD
PIK3CG
PIK3R1
PIM1
PLCB4
PLCG1
PMS2
POLD1
POLE
PP2R1A
PTCH1
PTEN
PTPN11
RAD50
RAD51C
RAD51D
RAF1
RB1
RBM10
RECQL
RET
RHEB
RICTOR
RIT1
RNF43
ROS1
RPTOR
RRMI
SDHB
SDHC
SETD2
SF3B1
SMAD1
SMAD2
SMAD4
SMAD5
SMAD9
SMARCA4
SMARCB1
SMO
SOCS1
SPOP
STAG2
STAT3
STAT5A
STAT5B
STK11
SUFU
TERT-p
TGFB1
TGFB2
TGFB3
TGFBR1
TGFBR2
TNFA1P3
TNK1
TOP2A
TP53
TSC1
TSC2
TSHR
TYMS
VEGFA
VHL
WTI
XRCC1
YES1
VIEW SINGLE IHC STAINS -and- TUMOR-SPECIFIC IHC PANELS
Single IHC Stains
MMR Panel
ALK
AR
CAIX
ER
hENTI
HER2
IDO
MET
MGMT
PD1
PD-L1 (22C3)
PD-L1 (SP142)
PR
PTEN
ROS1
TOP1
TP
TRKpan
TS
TUBB3
MLH1
MSH2
MSH6
PMS2
Tumor-Specific Panels
Anal Carcinoma: PD-L1 (22C3), PD-1, TS, TUBB3
Appendix: HER2, PD-L1 (22C3), TOP1, PTEN
Bladder: PD-L1 (22C3), PD-L1 (SP142), hENTI, TUBB3
Bone Cancer: TOP1, MGMT, CAIX, HENTI
Breast: AR, PD-L1(SP142), PD-L1 (22C3), TP
CNS / Brain Cancers: MGMT, CAIX, TUBB3, TOP1
Cervical: PD-L1 (22C3), CAIX, hENTI, TOP1
Colorectal: HER2, PD-L1 (22C3), TOP1, PTEN, TS
Gastric / Esophageal: HER2, PD-L1 (22C3), PTEN, TS
GIST: PD-L1 (22C3), MET
Head and Neck: PD-L1 (22C3), CAIX, TUBB3, PTEN
Head and Neck Salivary Gland: HER2, AR, CAIX, PTEN
Hepatobillary / Cholangiocarcinoma: hENTI, HER2, TP, PD-L1 (22C3)
Hepatobillary / Gallbladder: hENTI, HER2, PD-L1 (22C3), TOP1
Hepatobillary / Hepatocellular: hENTI, PD-L1 (22C3), CAIX, MET
Kidney: PD-L1 (22C3), MET, CAIX, hENTI
Melanoma: PD-L1 (22C3), MGMT, PTEN, TUBB3
Mesothelioma: PD-L1 (22C3), TS, hENTI, TUBB3
MMR: MLH1, MSH2, MSH6, PMS2
Neuroendocrine: PD-L1 (22C3), MGMT, PTEN, TP
NSCLC: PD-L1 (22C3), ALK, PD-L1 (SP142), PTEN, TS
Ovarian: ER, HER2, TOP1, TUBB3
Pancreatic: hENTI, PTEN, TP, TOP1
Penile Cancer: PD-L1 (22C3), TP, CAIX, TUBB3
Prostate: AR, PTEN, TUBB3, PD-L1 (22C3)
Sarcoma: CAIX, TUBB3, TOP1, MGMT
SCLC: PD-L1 (22C3), TOP1, MGMT
Small Bowel: TOPO1, CAIX, TUBB3, hENTI
Testicular Cancer: PD-L1 (22C3), TUBB3, hENTI
Thyroid: PD-L1 (22C3), ALK, TUBB3, CAIX
Thymoma / Thymic Carcinoma: PD-L1 (22C3), TUBB3, hENTI, TS
Uterine: PD-L1 (22C3), HER2, MGMT, TUBB3
Uveal Melanoma: PD-L1 (22C3), MGMT, TUBB3
Vulvar Cancer: PD-L1 (22C3), CAIX, TUBB3, hENTI
Other Solid Tumors: PD-L1 (22C3), HER2, TOP1, PTEN, TS

Download NSCLC Sample Report PDF


Oncotype MAP Pan-Cancer Tissue test focuses on therapy selection for today and captures emerging markers that may find their way into guidelines tomorrow.

REFERENCES

*Data on File, In-house assay optimization protected by trade-secret and patent applications.
† Turnaround time is based on qualified sample receipt.
‡ Morris S, Subramanian J, Gel E, Runger G, Thompson E, Mallery D, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE. (2018); 13(4): e0196556. https://doi.org/10.1371/journal.pone.0196556

Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.